2.003 hasil
Menampilkan 1–20 · 0,90 detik · RSS
Journal of Hematology & Oncology
Scopus
ISSN 1756-8722 · BMC · 2.003 artikel di indeks
-
Artikel Jurnal
CBX3 confers ferroptosis resistance during blood-borne metastasis
Abstract The survival mechanisms of circulating tumor cells (CTCs) remain poorly understood while these rare cell populations transit through the blood stream and colonize distant organs including the brain. Using single-cell RNA-seq of microfluidically-enriched CTCs and patient-matched brain…
-
Artikel Jurnal
Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma
Abstract Background CD19-directed chimeric antigen receptor T-cell therapy (CD19-CAR) has yielded encouraging efficacy in CNS lymphomas (CNSL), but most patients ultimately experience progressive disease (PD). Risk factors, progression patterns as well as optimal salvage therapies remain unclear…
-
Artikel Jurnal
Multiple myeloma risk linked to DNA damage response genes
Abstract Background DNA damage response genes (DDRG), implicated in several cancers as both predisposing risk factors as well as biomarkers for aggressiveness, have not been fully explored in multiple myeloma (MM). Methods Herein, we analyzed disease associations of pathogenic variations in nine…
-
Artikel Jurnal
Molecularly targeted therapy and immunotherapy in leukemias
Abstract The advent of next-generation high-throughput sequencing and precision medicine has allowed the identification of recurrent genetic events of vital interest for leukemic cells and for the management of patients with leukemia, since it has a direct impact on prognosis and therapeutic…
-
Artikel Jurnal
BCMA-CD19 armored compound CAR T cells in systemic lupus erythematosus: extended follow-up of a phase 1 clinical trial
Abstract CD19 CAR T-cells have shown promise in treating systemic lupus erythematosus (SLE), however, relapses demonstrate persistently elevated autoantibodies characteristic of CD19-negative long-lived plasma cells (LLPCs). Alternatively, ICG318, a dual-targeting BCMA–CD19 armored CAR T-cell…
-
Artikel Jurnal
Clinical validation of UroCAD test for upper tract urothelial carcinoma detection: results from a prospective multi-center study
Abstract Background Upper tract urothelial carcinoma (UTUC) poses diagnostic challenges due to its anatomical complexity and limited accessibility. Methods This prospective multicenter study (NCT05043662) evaluated the diagnostic performance of UroCAD, a novel non-invasive assay based on…
-
Artikel Jurnal
A subcellular spatial atlas illuminates the microenvironmental remodeling of perineural invasion in distal cholangiocarcinoma
Abstract Distal cholangiocarcinoma (dCCA) arises from the distal bile duct and is anatomically embedded within the pancreatic head, adjacent to abundant autonomic nerve plexuses. This unique location renders dCCA particularly prone to perineural invasion (PNI), a pathological hallmark that…
-
Artikel Jurnal
Multicenter real-life evaluation of the Post-CAR prognostic index for patients with large B-cell lymphoma after CAR-T failure
Abstract Most patients with large B-cell lymphoma (LBCL) progressing after CAR-T therapy experience poor survival and lack standardized treatment strategies. Prognostic tools are needed to guide decision-making at relapse. The Post-CAR Prognostic Index (PC-PI), recently proposed by Iacoboni et al…
-
Artikel Jurnal
Lung cancer vaccines to enhance immune checkpoint inhibitor therapy: evidence and future perspectives
Abstract Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of lung cancer over the past decade, markedly improving antitumor responses, overall survival, and quality of life. However, durable clinical benefit is achieved in only a subset of patients, and resistance to…
-
Artikel Jurnal
Implementing generative artificial intelligence in precision oncology: safety, governance, and significance
Abstract The paramount challenge in precision oncology lies in further improving quality of life and response rates for individual patients. Efforts toward these goals are steadily expanding the scope of clinical implementation, despite ongoing challenges such as standardization…
-
Artikel Jurnal
The distinct roles of ROS in tumor immunity: from mechanisms to immunotherapeutic applications
Abstract Reactive oxygen species (ROS) are crucial signaling molecules that regulate diverse biological processes. In cancer, this duality gives rise to a central paradox. Moderate ROS levels support tumor proliferation and foster an immunosuppressive microenvironment, whereas excessive ROS can be…
-
Artikel Jurnal
Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis
Abstract Background Ciltacabtagene autoleucel (cilta-cel) is a BCMA-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed or refractory multiple myeloma (RRMM). Following the CARTITUDE-1 results in heavily pretreated patients, the randomized phase 3 CARTITUDE-4 trial…
-
Artikel Jurnal
CD20-directed antibody-drug conjugates in non-hodgkin lymphoma: translating preclinical promise into clinical reality
Abstract Despite the paradigm-shifting success of anti-CD20 monoclonal antibodies like rituximab, limitations such as antigen loss, impaired host immune effector functions, and resistance remain key challenges in non-Hodgkin lymphoma (NHL). Antibody-drug conjugates (ADCs) targeting CD20 represent a…
-
Artikel Jurnal
Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition)
Abstract Gastric and gastroesophageal junction adenocarcinoma (GC/GEJC) poses a substantial clinical burden in China. This updated guideline introduces a refined human epidermal growth factor receptor 2 (HER2) classification system (high, intermediate, low, absent) to redefine patient…
-
Artikel Jurnal
Cytokines and cancer-associated fibroblasts
Abstract Cancer-associated fibroblast (CAF) is the dominant stromal component within the tumor microenvironment (TME), driving tumor malignancy through complex cell-to-cell communication, with cytokines serving as the fundamental communication medium. In this review, we systematically categorize…
-
Artikel Jurnal
Nanotechnology-enhanced CAR-T therapy strategies in cancer, aging, and autoimmune diseases
Abstract Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a transformative immunotherapy, which achieves remarkable success in hematological malignancies. However, broader application of CAR-T therapy is hindered by multiple challenges, including limited efficacy in solid tumors…
-
Artikel Jurnal
Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming
Abstract Antibody–drug conjugates (ADCs) have emerged as an important therapeutic strategy for breast cancer, particularly in the context of its molecular heterogeneity. Initially developed as targeted cytotoxic delivery systems, ADCs are increasingly being explored as multifunctional platforms…
-
Artikel Jurnal
Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies
Abstract Claudin18.2 (CLDN18.2) is primarily expressed in gastric epithelial cells, where it plays a crucial role in maintaining the integrity of the gastric mucosal barrier. Its aberrant expression is closely associated with the initiation, progression, and tumor microenvironment (TME) remodeling…
-
Artikel Jurnal
Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting
Abstract Although covalent and non-covalent Bruton tyrosine kinase inhibitors (BTKi) have extended clinical benefit to relapsed/refractory (R/R) and BTKi-resistant chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), there remains an unmet need for additional B-cell receptor (BCR)…
-
Artikel Jurnal
Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013
Abstract Background The previous Italian national trial (AIEOP-AML-2002/01) on children with acute myeloid leukemia (AML) achieved a 3-year overall (OS) and event-free survival (EFS) of 72.3% and 59.1%, respectively. In this study (AIEOP-AML-2013), we evaluated if refined patient’s stratification…
Menampilkan maksimal 50 halaman. Persempit pencarian dengan filter untuk hasil yang lebih spesifik.